Forte Biosciences (37T) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

37T Analyst Ratings

Moderate Buy

2 Buy

4 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Forte

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

37T Stock 12 Month Forecast

Average Price Target

€64.28

▼(-3.34% Downside)

Based on 6 Wall Street analysts offering 12 month price targets for Forte Biosciences in the last 3 months. The average price target is €64.28 with a high forecast of €66.88 and a low forecast of €52.98. The average price target represents a -3.34% change from the last price of €66.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","22":"€22","37":"€37","52":"€52","67":"€67"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66.88138226,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€66.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.27561412,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€64.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.98395218,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€52.98</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,22,37,52,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.5,66.52933709692307,66.55867419384616,66.58801129076923,66.6173483876923,66.64668548461539,66.67602258153846,66.70535967846153,66.7346967753846,66.76403387230769,66.79337096923076,66.82270806615384,66.85204516307692,{"y":66.88138226,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.5,66.32889339384616,66.1577867876923,65.98668018153846,65.81557357538462,65.64446696923076,65.47336036307692,65.30225375692308,65.13114715076924,64.96004054461538,64.78893393846154,64.6178273323077,64.44672072615384,{"y":64.27561412,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,66.5,65.46030401384616,64.42060802769231,63.380912041538465,62.34121605538461,61.30152006923077,60.261824083076924,59.22212809692308,58.182432110769234,57.14273612461538,56.10304013846154,55.06334415230769,54.02364816615385,{"y":52.98395218,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.6,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.5,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€66.88

Average Price Target€64.28

Lowest Price Target€52.98

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yaron Werber

TD Cowen

€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Forte Biosciences downgraded to Hold from Buy at TD CowenForte Biosciences downgraded to Hold from Buy at TD Cowen

Etzer Darout

Barclays

€64.28→€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Barclays downgrades Forte Biosciences (FBRX) to a Hold

Gavin Clark-Gartner

Evercore ISI

€59.93→€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Forte Biosciences (FBRX) was downgraded to a Hold Rating at Evercore ISI

Kumaraguru Raja

Brookline Capital Markets

€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Forte Biosciences downgraded to Hold from Buy at BrooklineForte Biosciences downgraded to Hold from Buy at Brookline

Yatin Suneja

Guggenheim

€65.14

Buy

-2.04%

Downside

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX), Sarepta Therapeutics (NASDAQ: SRPT) and Opus Genetics (NASDAQ: IRD)

Daniil Gataulin

Chardan Capital

€52.98

Buy

-20.32%

Downside

Reiterated

05/11/26

Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yaron Werber

TD Cowen

€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Forte Biosciences downgraded to Hold from Buy at TD CowenForte Biosciences downgraded to Hold from Buy at TD Cowen

Etzer Darout

Barclays

€64.28→€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Barclays downgrades Forte Biosciences (FBRX) to a Hold

Gavin Clark-Gartner

Evercore ISI

€59.93→€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Forte Biosciences (FBRX) was downgraded to a Hold Rating at Evercore ISI

Kumaraguru Raja

Brookline Capital Markets

€66.88

Hold

0.57%

Upside

Downgraded

07/27/26

Forte Biosciences downgraded to Hold from Buy at BrooklineForte Biosciences downgraded to Hold from Buy at Brookline

Yatin Suneja

Guggenheim

€65.14

Buy

-2.04%

Downside

Reiterated

07/09/26

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX), Sarepta Therapeutics (NASDAQ: SRPT) and Opus Genetics (NASDAQ: IRD)

Daniil Gataulin

Chardan Capital

€52.98

Buy

-20.32%

Downside

Reiterated

05/11/26

Analysts Are Bullish on Top Healthcare Stocks: Aktis Oncology, Inc. (AKTS), Metagenomi, Inc. (MGX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

TNYATenaya Therapeutics

JBIOJade Biosciences

GHRSGH Research

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Forte Biosciences

3 Months

Daniil GataulinChardan Capital

Success Rate

3/3 ratings generated profit

Average Return

+95.40%

Copying Daniil Gataulin's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +95.40% per trade.

1 Year

Yatin SunejaGuggenheim

Success Rate

3/3 ratings generated profit

Average Return

+283.77%

Copying Yatin Suneja's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +283.77% per trade.

2 Years

Daniil GataulinChardan Capital

Success Rate

3/3 ratings generated profit

Average Return

+333.33%

Copying Daniil Gataulin's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +333.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

37T Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 37T has received 2 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 37T average Analyst price target in the past 3 months is 64.28.

Each month's total comprises the sum of three months' worth of ratings.

37T Financial Forecast

37T Earnings Forecast

Next quarter’s earnings estimate for 37T is -€0.76 with a range of -€0.94 to -€0.44. The previous quarter’s EPS was -€1.08. 37T beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year 37T has Performed in-line its overall industry.

No data currently available

37T Sales Forecast

Next quarter’s sales forecast for 37T is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were ―. 37T beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year 37T has Performed in-line its overall industry.

37T Stock Forecast FAQ

What is DE:37T’s average 12-month price target, according to analysts?

Based on analyst ratings, Forte Biosciences Inc.’s 12-month average price target is 64.28.

What is DE:37T’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:37T, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Forte Biosciences Inc. a Buy, Sell or Hold?

Forte Biosciences Inc. has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.

What is Forte Biosciences Inc.’s share price target?

The average share price target for Forte Biosciences Inc. is 64.28. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €66.88 ,and the lowest forecast is €52.98. The average share price target represents -3.34% Decrease from the current price of €66.5.

What do analysts say about Forte Biosciences Inc.?

Forte Biosciences Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Forte Biosciences Inc.?

To buy shares of DE:37T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Forte Biosciences (37T) Stock Forecast & Price Target

37T Analyst Ratings

37T Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Forte Biosciences

37T Analyst Recommendation Trends

37T Financial Forecast

37T Earnings Forecast

37T Sales Forecast

37T Stock Forecast FAQ

Detailed List of Analyst Forecasts